Close

Wall Street ends flat as banks gain, Apple drags

Go back to Wall Street ends flat as banks gain, Apple drags

Leerink Partners Upgrades Sarepta Therapeutic (SRPT) to Market Perform

September 19, 2016 1:29 PM EDT

Leerink Partners upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Underperform to Market Perform with a price target of $50.00 (from $5.00).

Analyst Joseph Schwartz commented, "Sarepta's eteplirsen (Exondys 51, Duchenne Muscular Dystrophy) surprisingly received FDA's accelerated approval (AA), in stark contrast to the FDA's negative commentary... More